Product Data Sheet

(S)-Willardiine

Cat. No.:HY-12499CAS No.:21416-43-3Molecular Formula: $C_7H_9N_3O_4$ Molecular Weight:199.16Target:iGluR


Pathway: Membrane Transporter/Ion Channel; Neuronal Signaling

Storage: Powder -20°C 3 years

4°C 2 years

In solvent -80°C 2 years

-20°C 1 year



SOLVENT & SOLUBILITY

In Vitro DMSO: < 1 mg/mL (ultrasonic) (insoluble or slightly soluble)

BIOLOGICAL ACTIVITY

Description (S)-Willardiine is a potent agonist of AMPA/kainate receptors with EC50 of 44.8 uM.IC50 value: 44.8 uM(EC50) [1]Target:

AMPA/kainate receptor agonistin vitro: The (S)- but not (R)-isomers of willardiine and 5-bromowillardiine were potent agonists, producing rapidly but incompletely desensitizing responses [1]. At a concentration of 1.8 mM, Ca2+ inhibited the currents induced by 100 microM willardiine by approximately 50% [2]. in vivo: In newborn mice (P5, histopathology at P10), local injection of the AMPA receptor agonist S-bromo-willardiine at day 5 after birth induced cortical damage and white

matter damage, which was reduced in a dose-dependent manner by the AMPA receptor antagonists [3].

IC₅₀ & Target Kainate Receptor

REFERENCES

[1]. Patneau DK, et al. Activation and desensitization of AMPA/kainate receptors by novel derivatives of willardiine. J Neurosci. 1992 Feb;12(2):595-606.

 $[2]. \ Fukushima\ T, et\ al.\ Calcium\ inhibits\ will ard iine-induced\ responses\ in\ kainate\ receptor\ GluR6(Q)/KA-2.\ Neuroreport.\ 2001\ Jan\ 22;12(1):163-7.$

[3]. Gressens P, et al. The effects of AMPA receptor antagonists in models of stroke and neurodegeneration. Eur J Pharmacol. 2005 Sep 5;519 (1-2):58-67.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Screening Libraries

Inhibitors

Proteins